Form 4: Charles River Laboratories CEO James C. Foster Reports Significant Equity Grant and Ownership Update

Charles River Laboratories' Chairman, President, and CEO, James C. Foster, reported the acquisition of 17,253 shares of common stock as restricted stock units and an internal transfer of shares, increasing his direct beneficial ownership.

Summary

• James C. Foster, Chairman, President, and CEO of Charles River Laboratories International, Inc. (CRL), reported changes in his beneficial ownership of company common stock.
• On May 30, 2025, Mr. Foster acquired 17,253 shares of common stock at a price of $135.63 per share. These shares are unvested restricted stock units (RSUs) that will vest annually on May 30, 2026, 2027, 2028, and 2029.
• An exempt transfer of 9,793 shares from Mr. Foster's indirect holdings to his direct holdings was also reported, as per Rule 16a-13.
• Following these transactions, Mr. Foster's direct beneficial ownership stands at 210,685 shares of common stock.
• His indirect beneficial ownership includes 4,048 shares (2022 GRAT), 20,000 shares (2024 GRAT), 20,000 shares (2025 GRAT), 230 shares (by Trust), 750 shares (By Trust), 2,250 shares (By Trust), and 10,000 shares (Held By Spouse).
• The total beneficial ownership (direct and indirect) amounts to 267,963 shares.

Sentiment

Score: 7

Explanation: The acquisition of restricted stock units by the CEO is generally a positive signal, indicating continued alignment of management interests with long-term shareholder value. No sales were reported.

Positives

• The acquisition of 17,253 restricted stock units aligns the CEO's interests with long-term shareholder value, as these units vest over several years.
• The grant of equity compensation to the Chairman, President, and CEO indicates continued confidence in his leadership and performance.

Negatives

• No negative transactions, such as sales of shares, were reported in this filing.

Risks

• The issuance of restricted stock units, while aligning interests, can lead to minor share dilution over time as they vest and convert to common stock.

Future Outlook

This Form 4 filing primarily details insider transactions and does not provide forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

As a standard insider transaction report (Form 4), this filing does not offer specific insights into broader industry trends or competitive dynamics. It reflects an individual executive's equity compensation and ownership structure within the life sciences research and drug discovery industry.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions across all industries.
• The grant of restricted stock units to a CEO is a common form of executive compensation, aligning management incentives with long-term shareholder value.
• Without specific compensation benchmarks for Charles River Laboratories' peers (e.g., LabCorp, IQVIA, Catalent), a detailed comparison of the size of this grant is not possible from this document alone. However, the structure of the award (vesting over multiple years) is consistent with best practices in corporate governance for executive equity incentives.

Stakeholder Impact

• Shareholders: Increased alignment of the CEO's long-term interests with shareholder value through equity compensation.
• Employees: The CEO's continued equity stake may signal stability and confidence in the company's future direction.

Next Steps

• The acquired restricted stock units will vest annually on May 30, 2026, May 30, 2027, May 30, 2028, and May 30, 2029.

Key Dates

Keywords

Charles River Laboratories, CRL, SEC Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, Equity Compensation, James C. Foster, CEO, Director, Stock Grant